Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
48.69
+1.19 (+2.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
Better Growth Stock: Moderna vs. CRISPR Therapeutics
March 05, 2023
Both stocks are ripe for a rebound.
Via
The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
March 04, 2023
Institutional investors might be on to something.
Via
The Motley Fool
3 Game-Changing Stocks to Buy in March
March 04, 2023
Innovation is in these companies' DNA.
Via
The Motley Fool
2 Soaring Stocks to Buy and Hold Through 2023 and Beyond
March 03, 2023
Investors are bidding up shares of these companies, and there are good reasons for doing so.
Via
The Motley Fool
10 Best Stocks to Buy in March 2023
March 01, 2023
These diversified growth stocks could add rocket fuel to your long-term investment portfolio.
Via
The Motley Fool
Expert Ratings for CRISPR Therapeutics
February 27, 2023
Via
Benzinga
Looking Into CRISPR Therapeutics's Return On Invested Capital
February 22, 2023
Via
Benzinga
Beat the Dow Jones With CRISPR Therapeutics Stock
February 17, 2023
If approved, CRISPR's first product may deliver blockbuster sales.
Via
The Motley Fool
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
Here's How Much You Can Make From Investing Your Tax Return Every Year
February 27, 2023
Doing this can strengthen your retirement plan.
Via
The Motley Fool
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Via
The Motley Fool
2 Bruised Growth Stocks to Buy While They're Cheap
February 21, 2023
Both are on the verge of fast growth, and they haven't had any major setbacks yet.
Via
The Motley Fool
SMID Cap Life Science Update: Are You An Investor Or Trader?
February 20, 2023
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.
Via
Talk Markets
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer
February 18, 2023
These two companies are on track to flourish through the end of the decade.
Via
The Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
February 10, 2023
The gene-editing business has loads of potential, but is it enough to make you rich?
Via
The Motley Fool
Ready to Buy the Dip? Consider This Gene Editing Stock
February 06, 2023
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.
Via
The Motley Fool
3 Prime Healthcare Takeover Targets
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
February 12, 2023
The time is right for each of these great stocks.
Via
The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
February 12, 2023
All of these players are cheap today considering their growth potential.
Via
The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
February 10, 2023
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?
Via
The Motley Fool
2 Biotech Stocks That Could Make You Richer
February 09, 2023
Patience will pay off with these two stocks.
Via
The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
February 09, 2023
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
Via
The Motley Fool
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
February 09, 2023
CRISPR shares are ripe for a rebound after dropping 46% last year.
Via
The Motley Fool
1 Beaten-Down Stock That Has a Lot to Prove in 2023
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
3 Top Stocks to Buy If There Is a Market Pullback
February 07, 2023
All three of these stocks performed well as the market fell in 2022.
Via
The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
February 06, 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
Via
The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
February 03, 2023
These stocks all fell by double digits last year.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.